Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub-classified as intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA), the latter comprising both perihilar cholangiocarcinoma (pCCA or Klatskin tumor), and distal cholangiocarcinoma (dCCA). The global incidence of CCA has increased worldwide in recent decades. Chronic inflammation of biliary epithelium and bile stasis represent the main risk factors shared by all CCA sub-types. When feasible, liver resection is the treatment of choice for CCA, followed by systemic chemotherapy with capecitabine. Liver transplants represent a treatment option in patients with very early iCCA, in referral centers only. CCA diagnosis is often performed at an advanced stage when CCA is unresectable. In this setting, systemic chemotherapy with gemcitabine and cisplatin represents the first treatment option, but the prognosis remains poor. In order to ameliorate patients' survival, new drugs have been studied in the last few years. Target therapies are directed against different molecules, which are altered in CCA cells. These therapies have been studied as second-line therapy, alone or in combination with chemotherapy. In the same setting, the immune checkpoints inhibitors targeting programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen-4 (CTLA-4), have been proposed, as well as cancer vaccines and adoptive cell therapy (ACT). These experimental treatments showed promising results and have been proposed as second- or third-line treatment, alone or in combination with chemotherapy or target therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Self-citationOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790 · cited 1×
“Entrectinib showed an ORR of 57% with a median duration of response not reached [129,130].”
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626 · cited 1×
“At present, the data on immunotherapy in the BTC is limited, but several trials are currently investigating the role of anti-CTLA-4 (such as ipilimumab or tremelimumab), anti-PD-1 (such as pembrolizumab or nivolumab) and anti-PD-L1 (such as durvalumab) [136,137].”
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399 · cited 1×
“The combinations of PD-1 and CTLA-4 blockade have shown good results in several tumor types [118,149,150] due to synergistic effects resulting in increased numbers of Tumor-in fi ltrating lymphocytes (TILs), decreased regulatory T (Tregs) cells, and overall improved inhibition of tumor growth…”
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Ah Lee, M., Kitano, M., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200015 · Cited by 1,217 · cited 1×
“Symposium was presented the TOPAZ-1 study, the fi rst phase III trial that demonstrated positive results with the addition of an immune checkpoint inhibitor to the standard of care in an unselected population [77,78].”
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904 · cited 1×
“The most common adverse events are hyperphosphatemia (55-81% of patients), which is secondary to inhibition of FGF23, and determines inhibition of phosphate absorption in the intestine and reducing phosphate reabsorption in the kidney [112,113].”
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780 · cited 1×
“Targeting gene mutations rather than ampli fi cations may also have potential (e.g., neratinib [120] .”
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725 · cited 1×
“Previous studies have reported an up to 400 (cid:1) fold higher risk for CCA in PSC patients compared to the general population with the co-existence of in fl ammatory bowel disease (IBD) further increasing the risk of malignancies with a signi fi cant impact on the patient ’ s prognosis [14,15].”
Darwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., Botha, J. F., Mezrich, J. D., Chapman, W. C., Schwartz, J. J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.008 · Cited by 597
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552 · cited 1×
“…combinations of PD-1 and CTLA-4 blockade have shown good results in several tumor types [118,149,150] due to synergistic effects resulting in increased numbers of Tumor-in fi ltrating lymphocytes (TILs), decreased regulatory T (Tregs) cells, and overall improved inhibition of tumor growth [151,152].”
Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0270 · Cited by 468
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284 · cited 1×
“While several recommendations have been published for surveillance of CCA in PSC, there is no common consensus on the best prevention strategy, even if performing scheduled imaging techniques is associated with better survival [16 − 18] .”
Fibroblast growth factor (FGF) signaling in development and skeletal diseases
Teven, C. M., Farina, E. M., Rivas, J., & Reid, R. R. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.09.005 · Cited by 237
Petrick, J. L., Yang, B., Altekruse, S. F., Van Dyke, A. L., Koshiol, J., Graubard, B. I., & McGlynn, K. A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186643 · Cited by 210 · cited 1×
“Caroli ' s disease is the choledochal cyst phenotype more frequently complicated by CCA, with a 38 (cid:1) fold higher risk for the iCCA and a 97 (cid:1) fold higher risk for the eCCA subtype [19].”
Ethun, C. G., Lopez-Aguiar, A. G., Anderson, D. J., Adams, A. B., Fields, R. C., Doyle, M. B., Chapman, W. C., Krasnick, B. A., Weber, S. M., Mezrich, J. D., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002574 · Cited by 191
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Barner-Rasmussen, N., Pukkala, E., Jussila, A., & Färkkilä, M. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1707277 · Cited by 80 · cited 1×
“Previous studies have reported an up to 400 (cid:1) fold higher risk for CCA in PSC patients compared to the general population with the co-existence of in fl ammatory bowel disease (IBD) further increasing the risk of malignancies with a signi fi cant impact on the patient ’ s prognosis [14,15].”
McNamara, M. G., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., Ryder, W. D., Barber, S., Gnanaranjan, C., Ghazaly, E., et al. (2021) · The Oncologist · doi:10.1002/onco.13598 · Cited by 25
Cited by
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Khosla, D., Misra, S., Chu, P. L., Guan, P., Nada, R., Gupta, R., Kaewnarin, K., Ko, T. K., Heng, H. L., Srinivasalu, V. K., et al. (2024) · Cancers · doi:10.3390/cancers16040801 · Cited by 44
Metadata
- Authors
- Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R. E., Longarini, R., Stagno, A. M., Cristoferi, L., Ciaccio, A., Cortinovis, D. L., Invernizzi, P., & Massironi, S.
- Venue
- Annals of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 27
- Issue
- 5
- Pages
- 100737
- ISSN
- 1665-2681 (ISSN-L)
- OpenAlex
- W4284880240
- Cited by
- 160
- References
- 20
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.